Financials Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 12/06/2025 BST			5-day change	1st Jan Change
4.630 ^USD	+1.09%		+5.47%	-3.34%

06-12	Vanda Pharmaceuticals Inc., Q1 2025 Earnings Call, May 07, 2025
06-10	Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S	CI

Projected Income Statement: Vanda Pharmaceuticals Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	248.2	268.7	254.4	192.6	198.8	227.7	318.3	366.6
Change	-	8.27%	-5.32%	-24.27%	3.18%	14.56%	39.78%	15.17%
EBITDA	-	45.01	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
EBIT ¹	27.24	42.16	6.329	-13.95	-40.66	-114.4	-40.21	-14.8
Change	-	54.8%	-84.99%	-320.45%	-191.43%	-181.43%	64.86%	63.2%
Interest Paid	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	31.66	42.36	11.3	6.339	-22.92	-96.96	-21.25	-2
Change	-	33.83%	-73.33%	-43.9%	-461.59%	-323.03%	78.08%	90.59%
Net income ¹	23.34	33.15	6.275	2.509	-18.9	-88.15	-22.71	-2
Change	-	42.06%	-81.07%	-60.02%	-853.29%	-366.38%	74.23%	91.19%
Announcement Date	10/02/21	23/02/22	08/02/23	07/02/24	13/02/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4
Net sales ¹	62.21	60.31	67.65	-	67.9	70.1	68.02	60.19	64.39	65.32	64.48	46.06	38.82	45.27	-	50.47	47.65	53.18	50.04	54.77	58.83	64.1	67.6	75.33	83.5	91.9
Change	-	-3.05%	12.18%	-	-	3.23%	-2.96%	-11.51%	6.97%	1.44%	-1.28%	-28.58%	-15.72%	16.63%	-	-	-5.59%	11.61%	-5.91%	9.44%	7.43%	8.95%	5.46%	11.44%	10.84%	10.06%
EBITDA	-	-	-	-	16.82	15.48	9.342	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-7.98%	-39.64%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBIT ¹	9.171	7.742	10.45	-	12.37	10.82	8.636	-7.669	3.461	3.908	6.629	-2.867	-5.995	-7.094	-	-10.15	-11	-10.28	-41.03	-25.27	-25.47	-22.68	-21.15	-15.07	-9.234	-2.482
Change	-	-15.58%	34.99%	-	-	-12.53%	-20.18%	-188.8%	145.13%	12.92%	69.63%	-143.25%	-109.1%	-18.33%	-	-	-8.42%	6.55%	-299.14%	38.41%	-0.79%	10.97%	6.74%	28.73%	38.73%	73.12%
Charge d'intérêts	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	11.09	8.401	10.92	10.43	12.6	10.72	8.61	-7.564	3.79	5.461	9.613	2.592	-0.12	-1.661	-	-5.516	-6.244	-6.497	-37.37	-21.5	-20.21	-17.87	-17.63	-11.74	-5.97	0.762
Change	-	-24.24%	30.03%	-4.54%	20.87%	-14.93%	-19.7%	-187.85%	150.11%	44.09%	76.03%	-73.04%	-104.63%	-1,284.17%	-	-	-13.2%	-4.05%	-475.16%	42.46%	6.01%	11.55%	1.35%	33.4%	49.16%	112.76%
Net income ¹	8.714	5.947	8.19	8.65	9.653	7.771	7.078	-6.43	2.574	3.27	6.861	1.52	0.137	-2.4	-4.146	-4.518	-5.324	-4.912	-29.49	-21.13	-19.91	-17.61	-17.63	-11.74	-6.079	0.3835
Change	-	-31.75%	37.72%	5.62%	11.6%	-19.5%	-8.92%	-190.84%	140.03%	27.04%	109.82%	-77.85%	-90.99%	-1,851.82%	-72.75%	-8.97%	-17.84%	7.74%	-500.45%	28.35%	5.79%	11.56%	-0.14%	33.4%	48.24%	106.31%
Announcement Date	05/08/20	28/10/20	10/02/21	05/05/21	28/07/21	03/11/21	23/02/22	05/05/22	03/08/22	02/11/22	08/02/23	27/07/23	08/11/23	07/02/24	09/05/24	31/07/24	06/11/24	13/02/25	07/05/25	-	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Vanda Pharmaceuticals Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Announcement Date	10/02/21	23/02/22	08/02/23	07/02/24	13/02/25	-	-	-

Estimates

Cash Flow Forecast: Vanda Pharmaceuticals Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024
CAPEX ¹	1.019	1.795	0.552	0.679	101	4.719
Change	-	76.15%	-69.25%	23.01%	14,781.89%	-95.33%
Free Cash Flow (FCF) ¹	33.7	38.52	48.22	32.34	-88.78	-18.72
Change	-	14.31%	25.2%	-32.93%	-374.48%	78.91%
Announcement Date	26/02/20	11/02/21	24/02/22	09/02/23	08/02/24	14/02/25

¹USD in Million

Estimates

Forecast Financial Ratios: Vanda Pharmaceuticals Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-	-	16.75%	-	-	-	-	-	-
EBIT Margin (%)	-	10.98%	15.69%	2.49%	-7.24%	-20.46%	-50.25%	-12.63%	-4.04%
EBT Margin (%)	-	12.76%	15.77%	4.44%	3.29%	-11.53%	-42.58%	-6.68%	-0.55%
Net margin (%)	-	9.4%	12.34%	2.47%	1.3%	-9.51%	-38.71%	-7.14%	-0.55%
FCF margin (%)	-	-	-	-	-	-10.3%	-	-	-
FCF / Net Income (%)	-	-	-	-	-	108.34%	-	-	-
Profitability
ROA	3.49%	3.35%	4.68%	0.64%	-1.36%	-3.9%	-	-	-
ROE	33.67%	5.4%	6.92%	1.22%	0.47%	-3.49%	-	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	-	-	-	-	2.37%	-	-	-
CAPEX / EBITDA (%)	-	-	-	-	-	-	-	-	-
CAPEX / FCF (%)	-	-	-	-	-	-23.05%	-	-	-
Items per share
Cash flow per share ¹	-	-	1.128	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
EPS ¹	-	0.42	0.58	0.11	0.04	-0.33	-1.493	-0.3867	-0.03
Change	-	-	38.1%	-81.03%	-63.64%	-925%	-352.52%	74.11%	92.24%
Nbr of stocks (in thousands)	-	54,692	55,712	56,590	57,532	58,308	58,934	58,934	58,934
Announcement Date	-	10/02/21	23/02/22	08/02/23	07/02/24	13/02/25	-	-	-